GBGudlaug Bjornsdottir

Gudlaug Bjornsdottir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gudlaug Bjornsdottir has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals with Non-Alcoholic Fatty Liver Disease: A Prospective Single-Arm Feasibility Study (Preprint)

    by Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Bartosz Dobies, Kolbrun Sveinsdottir, Ari Pall Isberg, Gudlaug E. A. Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, et al.

    Background: A 3-month digital health program for NAFLD previously showed feasibility in engagement, program retention and clinical outcomes. This study investigates whether improvements in cardiometabolic risk factors achieved during a 3-month active program were sustained over a subsequent 6-month follow-up period. Objective: To evaluate whether the clinical improvements achieved after 3 months program were maintained over the subsequent 6-month period. Methods: In a 9-month, single-arm study using the Sidekick app, individuals with NAFLD and BMI>30 or metabolic syndrome, or type 2 diabetes (T2D) were included. The initial 3 months focused on providing education about diet, physical activity, stress management, and sleep followed by 6 months without coaching. The measured outcomes encompassed demographics, body composition, liver fat and blood markers. Results: Of 38 participants enrolled, 28 (82%) completed the nine-month study measurements 63.0 years (IQR 53.5-71.0) , 57.1% female). At nine months, the mean weight loss was 4.0 kg (SD 5.0, P<.001) compared to baseline. Liver fat decreased by 2.5% (SD 4.5, P<.001), with an 18.4% relative reduction. Systolic blood pressure decreased by 8.3 mmHg (SD 13.4, P<.001) and diastolic by 1.0 mmHg (SD 2.4, P=.02). Waist circumference decreased by 4.7 cm (SD 7.1, P<.001) and median HbA1c decreased by 18.5 mmol/mol (P<.001). Conclusions: Sustained improvements in liver fat and metabolic markers suggest that Sidekick Health’s digital program is a promising strategy for managing NAFLD without requiring continuous coaching. Clinical Trial: Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382


  • Open Access

    Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals with Non-Alcoholic Fatty Liver Disease: A Prospective Single-Arm Feasibility Study (Preprint)

    by Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Bartosz Dobies, Kolbrun Sveinsdottir, Ari Pall Isberg, Gudlaug E. A. Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, et al.

    BACKGROUND A 3-month digital health program for NAFLD previously showed feasibility in engagement, program retention and clinical outcomes. This study investigates whether improvements in cardiometabolic risk factors achieved during a 3-month active program were sustained over a subsequent 6-month follow-up period. OBJECTIVE To evaluate whether the clinical improvements achieved after 3 months program were maintained over the subsequent 6-month period. METHODS In a 9-month, single-arm study using the Sidekick app, individuals with NAFLD and BMI>30 or metabolic syndrome, or type 2 diabetes (T2D) were included. The initial 3 months focused on providing education about diet, physical activity, stress management, and sleep followed by 6 months without coaching. The measured outcomes encompassed demographics, body composition, liver fat and blood markers. RESULTS Of 38 participants enrolled, 28 (82%) completed the nine-month study measurements 63.0 years (IQR 53.5-71.0) , 57.1% female). At nine months, the mean weight loss was 4.0 kg (SD 5.0, P<.001) compared to baseline. Liver fat decreased by 2.5% (SD 4.5, P<.001), with an 18.4% relative reduction. Systolic blood pressure decreased by 8.3 mmHg (SD 13.4, P<.001) and diastolic by 1.0 mmHg (SD 2.4, P=.02). Waist circumference decreased by 4.7 cm (SD 7.1, P<.001) and median HbA1c decreased by 18.5 mmol/mol (P<.001). CONCLUSIONS Sustained improvements in liver fat and metabolic markers suggest that Sidekick Health’s digital program is a promising strategy for managing NAFLD without requiring continuous coaching. CLINICALTRIAL Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382

  • Open Access

    User Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study

    by Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Kolbrun Sveinsdottir, Ari Pall Isberg, Bartosz Dobies, Gudlaug Erla Akerlie Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, et al.

    Background: Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world. Common comorbidities are central obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome. Cardiovascular disease is the most common cause of death among people with NAFLD, and lifestyle changes can improve health outcomes. Objective: This study aims to explore the acceptability of a digital health program in terms of engagement, retention, and user satisfaction in addition to exploring changes in clinical outcomes, such as weight, cardiometabolic risk factors, and health-related quality of life. Methods: We conducted a prospective, open-label, single-arm, 12-week study including 38 individuals with either a BMI >30, metabolic syndrome, or type 2 diabetes mellitus and NAFLD screened by FibroScan. An NAFLD-specific digital health program focused on disease education, lowering carbohydrates in the diet, food logging, increasing activity level, reducing stress, and healthy lifestyle coaching was offered to participants. The coach provided weekly feedback on food logs and other in-app activities and opportunities for participants to ask questions. The coaching was active throughout the 12-week intervention period. The primary outcome was feasibility and acceptability of the 12-week program, assessed through patient engagement, retention, and satisfaction with the program. Secondary outcomes included changes in weight, liver fat, body composition, and other cardiometabolic clinical parameters at baseline and 12 weeks. Results: In total, 38 individuals were included in the study (median age 59.5, IQR 46.3-68.8 years; n=23, 61% female). Overall, 34 (89%) participants completed the program and 29 (76%) were active during the 12-week program period. The median satisfaction score was 6.3 (IQR 5.8-6.7) of 7. Mean weight loss was 3.5 (SD 3.7) kg (P<.001) or 3.2% (SD 3.4%), with a 2.2 (SD 2.7) kg reduction in fat mass (P<.001). Relative liver fat reduction was 19.4% (SD 23.9%). Systolic blood pressure was reduced by 6.0 (SD 13.5) mmHg (P=.009). The median reduction was 0.14 (IQR 0-0.47) mmol/L for triglyceride levels (P=.003), 3.2 (IQR 0.0-5.4) µU/ml for serum insulin (s-insulin) levels (P=.003), and 0.5 (IQR –0.7 to 3.8) mmol/mol for hemoglobin A1c (HbA1c) levels (P=.03). Participants who were highly engaged (ie, who used the app at least 5 days per week) had greater weight loss and liver fat reduction. Conclusions: The 12-week-long digital health program was feasible for individuals with NAFLD, receiving high user engagement, retention, and satisfaction. Improved liver-specific and cardiometabolic health was observed, and more engaged participants showed greater improvements. This digital health program could provide a new tool to improve health outcomes in people with NAFLD. Trial Registration: Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382


  • Open Access

    User Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study (Preprint)

    by Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Kolbrun Sveinsdottir, Ari Pall Isberg, Bartosz Dobies, Gudlaug Erla Akerlie Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, et al.

    BACKGROUND Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world. Common comorbidities are central obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome. Cardiovascular disease is the most common cause of death among people with NAFLD, and lifestyle changes can improve health outcomes. OBJECTIVE This study aims to explore the acceptability of a digital health program in terms of engagement, retention, and user satisfaction in addition to exploring changes in clinical outcomes, such as weight, cardiometabolic risk factors, and health-related quality of life. METHODS We conducted a prospective, open-label, single-arm, 12-week study including 38 individuals with either a BMI >30, metabolic syndrome, or type 2 diabetes mellitus and NAFLD screened by FibroScan. An NAFLD-specific digital health program focused on disease education, lowering carbohydrates in the diet, food logging, increasing activity level, reducing stress, and healthy lifestyle coaching was offered to participants. The coach provided weekly feedback on food logs and other in-app activities and opportunities for participants to ask questions. The coaching was active throughout the 12-week intervention period. The primary outcome was feasibility and acceptability of the 12-week program, assessed through patient engagement, retention, and satisfaction with the program. Secondary outcomes included changes in weight, liver fat, body composition, and other cardiometabolic clinical parameters at baseline and 12 weeks. RESULTS In total, 38 individuals were included in the study (median age 59.5, IQR 46.3-68.8 years; n=23, 61% female). Overall, 34 (89%) participants completed the program and 29 (76%) were active during the 12-week program period. The median satisfaction score was 6.3 (IQR 5.8-6.7) of 7. Mean weight loss was 3.5 (SD 3.7) kg (P<.001) or 3.2% (SD 3.4%), with a 2.2 (SD 2.7) kg reduction in fat mass (P<.001). Relative liver fat reduction was 19.4% (SD 23.9%). Systolic blood pressure was reduced by 6.0 (SD 13.5) mmHg (P=.009). The median reduction was 0.14 (IQR 0-0.47) mmol/L for triglyceride levels (P=.003), 3.2 (IQR 0.0-5.4) µU/ml for serum insulin (s-insulin) levels (P=.003), and 0.5 (IQR –0.7 to 3.8) mmol/mol for hemoglobin A1c (HbA1c) levels (P=.03). Participants who were highly engaged (ie, who used the app at least 5 days per week) had greater weight loss and liver fat reduction. CONCLUSIONS The 12-week-long digital health program was feasible for individuals with NAFLD, receiving high user engagement, retention, and satisfaction. Improved liver-specific and cardiometabolic health was observed, and more engaged participants showed greater improvements. This digital health program could provide a new tool to improve health outcomes in people with NAFLD. CLINICALTRIAL Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382